target downgrad unit state go sg websit
mix result due softer-than-expect diabet inflamm sale
upsid tp
nc chang
despit better-than-expect earn help lower tax rate eli
report sale line consensu octob group flag
softer perform diabet sale taltz inflamm due
us price pressur market expect pipelin alreadi high
stock trade full valuat multipl reflect earn growth
shade ahead sector reiter hold rate trim tp
edg mid-term oper margin
expect factor lower peer group multipl
sale perform less line group sale grew constant
exchang rate cer broadli line consensu despit mix diabet portfolio
perform basaglar biosimilar version sanofi lantu miss consensu
jardianc miss trulic diabet weekli
direct competitor novo ozemp saw growth still miss
consensu price pressur us explain miss
diabet market face tough competit eli guid mid-singl digit annual
price declin trulic price pressur compound neg hit
call donut hole rise sale lower price channel contrast human
short-act insulin old gener sale better expect
howev sale recent launch taltz light consensu
despit grow prescript us eli made signific rebat payer
note direct competitor cosentyx/novarti beat ciali erectil disfunct
drop due gener eros albeit slightli milder declin expect
ep beat adj oper incom fell due due higher cog
adj ep reach consensu despit oper margin line
beat explain lower tax rate vs con thank
tax benefit tax audit resolut us tax reform non-gaap ep guidanc
rais reflect lower tax rate rise incom eli look
consensu stand slightli low end rang
hold reiter adjust estim reflect result lower tax
rate cut tp due lower peer multipl lower mid-term
oper margin price pressur build consensu expect pipelin
alreadi high stock trade price-to-earnings premium pharma
sector think above-sector earn growth vs driven portfolio
rejuven despit patent expiri alreadi less price
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor
make invest decis pleas appendix end report analyst certif
simplifi select product
tp adjust vs
lt growth wacc nc lt ebita margin
trulic us total prescript market volum
basaglar long act insulin biosimilar version sanofi
lantu us total prescript market volum
jardianc us total prescript market volum
heart failur preserv eject
heart failur reduc eject
class tremfya
class tremfya
surpass programm seven trial read
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet oct cet
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report florent cesped
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan geneva seoul warsaw moscow
tp deriv sotp dcf order captur short term perform lt opportun pipelin sotp
averag valuat given use larg pharma ev/ebita multipl premium pharma divis dcf lt growth
downsid gener threat steadi eros rate tail portfolio group sale
upsid recent launch product cancer diabet immuno-inflamm drive mid-singl digit top-line growth
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
equiti rate dispers relationship
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin
use creat financi product includ indic inform provid basi user assum entir
risk use made inform affili third parti involv relat comput compil
inform herebi expressli disclaim warranti origin accuraci complet merchant fit particular
purpos respect inform without limit forego event shall affili
third parti involv relat comput compil inform liabil damag kind morgan
stanley capit intern index servic mark affili similar languag may
provid approv advanc
